The biopharma industry recorded 62 layoff rounds in Q3 2025, consistent with previous quarters and on track to surpass 2024's total by 27%. Notably, Novo Nordisk cut 9,000 jobs, Merck eliminated 6,000 positions under CEO Doustdar to save billions, and Sarepta Therapeutics cut 36% of its workforce while pivoting pipeline focus and facing FDA warnings. These trends highlight strategic restructuring and investor caution within gene therapy and large pharma sectors.